ଟେବେଣ୍ଟାଫସ୍ପ

ଟେବେଣ୍ଟାଫସ୍ପ
Clinical data
Trade names	Kimmtrak
Synonyms	IMCgp100, tebentafusp-tebn
AHFS/Drugs.com	monograph
data	US DailyMed: Tebentafusp;
Pregnancy; category	AU: C ; ;
Routes of; administration	Intravenous
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only / Schedule D; US: ℞-only ; EU: Rx-only ;

ଟେବେଣ୍ଟାଫସ୍ପ (ଇଂରାଜୀ ଭାଷାରେ Tebentafusp), କିମଟ୍ରାକ୍ ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଯୁଭିଆଲ ମେଲାନୋମା ନାମକ ଏକ ପ୍ରକାର ଆଖି କର୍କଟ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ଏହା ଏହା ଏଚଏଲଏ-ଏ *୦୨: ୦୧-ସକରାତ୍ମକ କ୍ଷେତ୍ରରେ (HLA-A*02:01-positive cases) ବ୍ୟବହୃତ ହୁଏ ଯାହା କେବଳ ଅସ୍ତ୍ରୋପଚାରଦ୍ୱାରା ଚିକିତ୍ସା ହୋଇପାରିବ ନାହିଁ ।^[୪] ^[୩] ଏହା ଏକ ଶିରାରେ ଇଞ୍ଜେକସ ଆକାରରେ ଦିଆଯାଏ ।^[୪] ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାର ବିପଦ ହେତୁ ପ୍ରାରମ୍ଭିକ ମାତ୍ରା ପରେ ପ୍ରାୟ ଏକ ଦିନର ନିୟନ୍ତ୍ରଣ ଓ ନିରୂପଣ ଆବଶ୍ୟକ ହୁଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସାଇଟୋକାଇନ୍ ରିଲିଜ୍ ସିଣ୍ଡ୍ରୋମ, ରାସ, ଜ୍ୱର, ଗଲୁ, ଥକାପଣ, ଅଇ, ପେଟ ଯନ୍ତ୍ରଣା, ଫୁଲା, ନିମ୍ନ ରକ୍ତଚାପ, ଶୁଷ୍କ ଚର୍ମ, ମୁଣ୍ଡବିନ୍ଧା ଏବଂ ବାନ୍ତି ହୋଇପାରେ ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୪] ଏହା ଏକ ବାଇସ୍ପେସିଫିକ ଜିପି ୧୦୦ ପେପ୍ଟାଇଡ-ଏଚଏଲଏ-ନିର୍ଦ୍ଦେଶିତ ସିଡି୩ଟି ଜୀବକୋଷ ଏନ‌ଗେଜର ।^[୪]

୨୦୨୨ ମସିହାରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଟେବେଣ୍ଟାଫସ୍ପ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୪] ^[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ଔଷଧର ଏକ ମାତ୍ରାର ମୂଲ୍ୟ ପ୍ରାୟ ୧୮,୮୦୦ ଡଲାର ଅଟେ । ^[୬] ଯୁକ୍ତରାଜ୍ୟରେ, ଏହା ଉପଲବ୍ଧ କିନ୍ତୁ ଏହାର ମୂଲ୍ୟ ଏପର୍ଯ୍ୟନ୍ତ ନିରୂପଣ କରାଯାଇ ନାହିଁ ।^[୬]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Kimmtrak". Therapeutic Goods Administration (TGA). 15 June 2022. Archived from the original on 18 June 2022. Retrieved 18 June 2022.
↑ "Kimmtrak Product information". Health Canada. 25 April 2012. Archived from the original on 1 October 2022. Retrieved 30 September 2022.
↑ ^୩.୦ ^୩.୧ ^୩.୨ "Kimmtrak EPAR". European Medicines Agency (EMA). 24 January 2022. Archived from the original on 22 April 2022. Retrieved 22 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ ^୪.୮ "Kimmtrak- tebentafusp injection, solution, concentrate". DailyMed. 26 January 2022. Archived from the original on 21 February 2022. Retrieved 20 February 2022.
↑ "FDA approves tebentafusp-tebn for unresectable". U.S. Food and Drug Administration (FDA). 25 January 2022. Archived from the original on 27 January 2022. Retrieved 28 January 2022. This article incorporates text from this source, which is in the public domain.
↑ ^୬.୦ ^୬.୧ "Tebentafusp". SPS - Specialist Pharmacy Service. 17 September 2019. Archived from the original on 19 October 2021. Retrieved 11 December 2022.

[Kimmtrak_APMDS-1] ୧.୦ ^୧.୧ "Kimmtrak". Therapeutic Goods Administration (TGA). 15 June 2022. Archived from the original on 18 June 2022. Retrieved 18 June 2022.

[2] "Kimmtrak Product information". Health Canada. 25 April 2012. Archived from the original on 1 October 2022. Retrieved 30 September 2022.

[EPAR2022-3] ୩.୦ ^୩.୧ ^୩.୨ "Kimmtrak EPAR". European Medicines Agency (EMA). 24 January 2022. Archived from the original on 22 April 2022. Retrieved 22 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ ^୪.୭ ^୪.୮ "Kimmtrak- tebentafusp injection, solution, concentrate". DailyMed. 26 January 2022. Archived from the original on 21 February 2022. Retrieved 20 February 2022.

[FDA_PR_20220125-5] "FDA approves tebentafusp-tebn for unresectable". U.S. Food and Drug Administration (FDA). 25 January 2022. Archived from the original on 27 January 2022. Retrieved 28 January 2022. This article incorporates text from this source, which is in the public domain.

[SPS2022-6] ୬.୦ ^୬.୧ "Tebentafusp". SPS - Specialist Pharmacy Service. 17 September 2019. Archived from the original on 19 October 2021. Retrieved 11 December 2022.

[୪]

[୩]

[୧]

[୨]

[୫]

[୬]